Drug Trial Radar · NCT07125261
BHV-7000 Responsive Neurostimulation System (RNS) Study
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Oct 7, 2025
Primary completion
Mar 18, 2026
Study completion Sep 16, 2026
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Biohaven Pharmaceuticals, Inc.
- First posted
- Aug 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label study to assess the biological effect of BHV-7000 on abnormal activity recorded by the RNS System in patients with focal epilepsy implanted with the RNS System. BHV-7000 is a potassium channel activator being evaluated for use in epilepsy. Participants are offered the drug for 4 weeks. Activity during that treatment period is compared to a 90-day retrospective baseline period in which other medications and device settings were stable, and also to a 4-week withdrawal period after treatment is discontinued. The study is open to patients with RNS regardless of whether they report clinical seizures, as long as the device recordings continue to show epileptiform activity.
Conditions
- Epilepsy
- Seizures
Interventions
BHV-700Drug
75 mg daily for the 4-week treatment period (dose which may be adjusted based on tolerability)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in patient-specific seizure surrogate rateTime frame: 28 days
- Reduction in seizure onset pattern rateTime frame: 28 days
- Reduction in long episode rateTime frame: 28 days
- Reduction in saturation rateTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yale Comprehensive Epilepsy Center
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.